TY - JOUR AU - Picardo, Sarah L. AU - Hansen, Aaron R. PY - 2019 TI - The PD-1/PD-L1 pathway in advanced prostate cancer—have we milked this cow? JF - Annals of Translational Medicine; Vol 7, No 14 (July 31, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - We would like to thank Dr. Fay and Dr. Antonarakis for their insightful comments on immunotherapy (IO) in advanced prostate cancer and specifically their commentary on the recently published KEYNOTE-028 study on the use of pembrolizumab in programmed cell death protein-1 ligand (PD-L1) positive metastatic castrate resistant prostate cancer (mCRPC) (1). As described by the authors, monotherapy with checkpoint inhibitors has not demonstrated the dramatic response rates in mCRPC that were shown in other cancer types such as melanoma and non-small cell lung cancer (NSCLC). UR - https://atm.amegroups.org/article/view/26389